Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

128.54 +0.91 (+0.71%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
49 50 Next >
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
The dividend growth powerhouse is turning the corner. 
Via The Motley Fool
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
The company continues to flex its innovative muscles. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
These stocks have increased their payouts for decades. 
Via The Motley Fool
Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors.
Is ABBOTT LABORATORIES (NYSE:ABT) a Strong Candidate for Quality Investing? 
Via Chartmill
Looking Into Abbott Laboratories's Recent Short Interest
 
Via Benzinga
Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
 
Via Benzinga
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
You can take these dividends straight to the bank. 
Via The Motley Fool
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases 
Via MarketBeat
Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System
Abbott recalls some FreeStyle Libre 3 sensors due to incorrect glucose readings, risking severe health issues. 
Via Benzinga
Topics Product Recall
Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device
The companies are now duking it out for a new population of CGM users. 
Via Investor's Business Daily
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
These three have secure core businesses, plus multiple paths to grow. 
Via The Motley Fool
Patchy But Still Bullish
Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations. 
Via Talk Markets
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a prescription. Designed for people with Type 2 diabetes and prediabetes, Stelo... 
Via Benzinga
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
The company is upbeat on its upcoming Stelo launch. The CGM is geared to people who don't use insulin. 
Via Investor's Business Daily
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
This MedTech leader is back on track with profitable growth. 
Via The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Some of Trump's Dividend Kings deserve a crown more than others. 
Via The Motley Fool
Topics Government
3 Unstoppable Dividend Stocks to Buy Right Now
These stocks are the A-team for income investors. 
Via The Motley Fool
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
Medtronic's Q1 FY2025 results were driven by its diabetes products, and new offerings in development or pending FDA approval could fuel future performance. 
Via MarketBeat
Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades'
Abbott Laboratories has a strong pipeline and the stock is starting to move, according to Karen Firestone of Aureus Asset Management. 
Via Benzinga
Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.
These stocks pay above-average yields, and their dividend income could rise higher in the future. 
Via The Motley Fool
Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
An unexpected diabetes partnership with Medtronic bodes well for Abbott's biggest growth driver. 
Via The Motley Fool
3 Stocks Retirees Should Absolutely Love
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
3 Dividend Growth Stocks to Buy Hand Over Fist in August
There are blue-chip bargains paying large and growing dividends in the healthcare space. 
Via The Motley Fool
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.